Literature DB >> 24337828

Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients.

Nobuharu Tamaki1, Masayuki Kurosaki, Shuya Matsuda, Masaru Muraoka, Yutaka Yasui, Shoko Suzuki, Takanori Hosokawa, Ken Ueda, Kaoru Tsuchiya, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Yasuhiro Asahina, Namiki Izumi.   

Abstract

BACKGROUND: The FIB-4 index is a simple formula to predict liver fibrosis. This study aimed to evaluate the utility of the FIB-4 index and associated time-course changes as a predictor of hepatocellular carcinoma (HCC) development.
METHODS: A total of 171 chronic hepatitis C patients who underwent paired liver biopsies and 875 patients who underwent a single liver biopsy (validation group) were investigated during mean follow-up periods of 6.4 and 5.9 years, respectively. All patients had received interferon therapy and had not achieved a sustained virological response. Factors associated with HCC development were analyzed in these patients.
RESULTS: HCC developed in 30 patients in the paired biopsy group and 89 patients in the validation group. Univariate analysis demonstrated that the FIB-4 index >3.25 and change in the FIB-4 index per year (ΔFIB-4/year) ≥ 0.3 were predictive factors for HCC development in both groups. Multivariate analysis in the combined population revealed that these two factors were independent. The hazard ratio (HR) for the FIB-4 index >3.25 was 2.7 (p < 0.001) and ΔFIB-4/year ≥ 0.3 was 1.8 (p = 0.003). Patients with a FIB-4 index >3.25 and a ΔFIB-4/year ≥ 0.3 were defined as high risk, and those with a FIB-4 index ≤ 3.25 and a ΔFIB-4/year <0.3 were defined as low risk. The HR of HCC development in patients at high risk was 7.3 (95% confidence interval 4.3-12.5, p < 0.001).
CONCLUSIONS: It was possible to define a group at high risk of developing HCC by intermittently measuring the FIB-4 index and considering time-course changes in this index.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24337828     DOI: 10.1007/s00535-013-0914-y

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  35 in total

1.  Pain experienced during percutaneous liver biopsy.

Authors:  L Castéra; I Nègre; K Samii; C Buffet
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

2.  Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection.

Authors:  David Nunes; Catherine Fleming; Gwynneth Offner; Donald Craven; Oren Fix; Timothy Heeren; Margaret J Koziel; Camilla Graham; Sheila Tumilty; Paul Skolnik; Sherri Stuver; C Robert Horsburgh; Deborah Cotton
Journal:  Am J Gastroenterol       Date:  2010-02-23       Impact factor: 10.864

3.  Chronic hepatitis B.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2007-02       Impact factor: 17.425

4.  Thrombocytopenia associated with hepatitis C viral infection.

Authors:  T Nagamine; T Ohtuka; K Takehara; T Arai; H Takagi; M Mori
Journal:  J Hepatol       Date:  1996-02       Impact factor: 25.083

5.  Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009).

Authors:  Izumi Namiki; Shuhei Nishiguchi; Keisuke Hino; Fumitaka Suzuki; Hiromitsu Kumada; Yoshihito Itoh; Yusuhiro Asahina; Akihiro Tamori; Naoki Hiramatsu; Norio Hayashi; Masatoshi Kudo
Journal:  Hepatol Res       Date:  2010-04       Impact factor: 4.288

6.  Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model.

Authors:  Xavier Forns; Sergi Ampurdanès; Josep M Llovet; John Aponte; Llorenç Quintó; Eva Martínez-Bauer; Miquel Bruguera; Jose Maria Sánchez-Tapias; Juan Rodés
Journal:  Hepatology       Date:  2002-10       Impact factor: 17.425

7.  Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients.

Authors:  Nobuharu Tamaki; Masayuki Kurosaki; Shuya Matsuda; Toru Nakata; Masaru Muraoka; Yuichiro Suzuki; Yutaka Yasui; Shoko Suzuki; Takanori Hosokawa; Takashi Nishimura; Ken Ueda; Kaoru Tsuchiya; Hiroyuki Nakanishi; Jun Itakura; Yuka Takahashi; Kotaro Matsunaga; Kazuhiro Taki; Yasuhiro Asahina; Namiki Izumi
Journal:  Hepatol Res       Date:  2013-07-10       Impact factor: 4.288

8.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

Authors:  Laurent Castéra; Julien Vergniol; Juliette Foucher; Brigitte Le Bail; Elise Chanteloup; Maud Haaser; Monique Darriet; Patrice Couzigou; Victor De Lédinghen
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

9.  The long-term pathological evolution of chronic hepatitis C.

Authors:  M Yano; H Kumada; M Kage; K Ikeda; K Shimamatsu; O Inoue; E Hashimoto; J H Lefkowitch; J Ludwig; K Okuda
Journal:  Hepatology       Date:  1996-06       Impact factor: 17.425

10.  The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy.

Authors:  Masayuki Kurosaki; Kotaro Matsunaga; Itsuko Hirayama; Tomohiro Tanaka; Mitsuaki Sato; Nobutoshi Komatsu; Naoki Umeda; Takanori Hosokawa; Ken Ueda; Kaoru Tsuchiya; Hiroyuki Nakanishi; Jun Itakura; Yasuhiro Asahina; Shozo Miyake; Nobuyuki Enomoto; Namiki Izumi
Journal:  J Hepatol       Date:  2008-02-26       Impact factor: 25.083

View more
  22 in total

1.  FIB-4 index for assessing the prognosis of hepatocellular carcinoma in patients with Child-Pugh class A liver function.

Authors:  Takanori Ito; Takashi Kumada; Hidenori Toyoda; Toshifumi Tada
Journal:  J Cancer Res Clin Oncol       Date:  2015-02-04       Impact factor: 4.553

2.  Comparison of AI techniques for prediction of liver fibrosis in hepatitis patients.

Authors:  Brian Keltch; Yuan Lin; Coskun Bayrak
Journal:  J Med Syst       Date:  2014-06-24       Impact factor: 4.460

Review 3.  Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC.

Authors:  Hidenori Toyoda; Takashi Kumada; Toshifumi Tada; Yasuhiro Sone; Yuji Kaneoka; Atsuyuki Maeda
Journal:  Liver Cancer       Date:  2015-03       Impact factor: 11.740

4.  Engagement in Care of High-Risk Hepatitis C Patients with Interferon-Free Direct-Acting Antiviral Therapies.

Authors:  John B Dever; Julie H Ducom; Ariel Ma; Joseph Nguyen; Lin Liu; Ann Herrin; Erik J Groessl; Samuel B Ho
Journal:  Dig Dis Sci       Date:  2017-04-04       Impact factor: 3.199

5.  Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence.

Authors:  Qing Pang; Jing-Yao Zhang; Xin-Sen Xu; Si-Dong Song; Kai Qu; Wei Chen; Yan-Yan Zhou; Run-Chen Miao; Su-Shun Liu; Ya-Feng Dong; Chang Liu
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

6.  Risk stratification of hepatocellular carcinoma incidence using a fibrosis-4-based prediction model in patients with chronic hepatitis C receiving antiviral therapy: a nationwide real-world Taiwanese cohort study.

Authors:  Hung-Wei Wang; Pei-Chein Tsai; Chi-Yi Chen; Kuo-Chih Tseng; Hsueh-Chou Lai; Hsing-Tao Kuo; Chao-Hung Hung; Shui-Yi Tung; Jing-Houng Wang; Jyh-Jou Chen; Pei-Lun Lee; Ron-Nan Chien; Chun-Yen Lin; Chi-Chieh Yang; Gin-Ho Lo; Chi-Ming Tai; Chih-Wen Lin; Jia-Horng Kao; Chun-Jen Liu; Chen-Hua Liu; Sheng-Lei Yan; Ming-Jong Bair; Wei-Wen Su; Cheng-Hsin Chu; Chih-Jen Chen; Ching-Chu Lo; Pin-Nan Cheng; Yen-Cheng Chiu; Chia-Chi Wang; Jin-Shiung Cheng; Wei-Lun Tsai; Han-Chieh Lin; Yi-Hsiang Huang; Jee-Fu Huang; Chia-Yen Dai; Wan-Long Chuang; Ming-Lung Yu; Cheng-Yuan Peng
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

7.  The FIB-4 index is a significant prognostic factor in patients with non-B non-C hepatocellular carcinoma after curative surgery.

Authors:  Yukiyasu Okamura; Ryo Ashida; Yusuke Yamamoto; Takaaki Ito; Teiichi Sugiura; Emima Bekku; Takeshi Aramaki; Katsuhiko Uesaka
Journal:  Langenbecks Arch Surg       Date:  2016-03-04       Impact factor: 3.445

Review 8.  Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease.

Authors:  Nobuharu Tamaki; Masayuki Kurosaki; Yutaka Yasui; Kaoru Tsuchiya; Namiki Izumi
Journal:  J Med Ultrason (2001)       Date:  2021-06-24       Impact factor: 1.314

9.  Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus.

Authors:  Nobuharu Tamaki; Masayuki Kurosaki; Yutaka Yasui; Nami Mori; Keiji Tsuji; Chitomi Hasebe; Koji Joko; Takehiro Akahane; Koichiro Furuta; Haruhiko Kobashi; Hiroyuki Kimura; Hitoshi Yagisawa; Hiroyuki Marusawa; Masahiko Kondo; Yuji Kojima; Hideo Yoshida; Yasushi Uchida; Rohit Loomba; Namiki Izumi
Journal:  Clin Infect Dis       Date:  2021-11-02       Impact factor: 9.079

10.  Evaluation of Fucosylated Haptoglobin and Mac-2 Binding Protein as Serum Biomarkers to Estimate Liver Fibrosis in Patients with Chronic Hepatitis C.

Authors:  Seiichi Tawara; Tomohide Tatsumi; Sadaharu Iio; Ichizou Kobayashi; Minoru Shigekawa; Hayato Hikita; Ryotaro Sakamori; Naoki Hiramatsu; Eiji Miyoshi; Tetsuo Takehara
Journal:  PLoS One       Date:  2016-03-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.